JP2022500425A5 - - Google Patents

Info

Publication number
JP2022500425A5
JP2022500425A5 JP2021514019A JP2021514019A JP2022500425A5 JP 2022500425 A5 JP2022500425 A5 JP 2022500425A5 JP 2021514019 A JP2021514019 A JP 2021514019A JP 2021514019 A JP2021514019 A JP 2021514019A JP 2022500425 A5 JP2022500425 A5 JP 2022500425A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
hydrogen
salt according
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514019A
Other languages
English (en)
Japanese (ja)
Other versions
JP7361766B2 (ja
JP2022500425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/057710 external-priority patent/WO2020053811A1/en
Publication of JP2022500425A publication Critical patent/JP2022500425A/ja
Publication of JP2022500425A5 publication Critical patent/JP2022500425A5/ja
Application granted granted Critical
Publication of JP7361766B2 publication Critical patent/JP7361766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514019A 2018-09-14 2019-09-12 ヒト免疫不全ウイルス複製の阻害剤 Active JP7361766B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862731196P 2018-09-14 2018-09-14
US62/731,196 2018-09-14
US201862733259P 2018-09-19 2018-09-19
US62/733,259 2018-09-19
PCT/IB2019/057710 WO2020053811A1 (en) 2018-09-14 2019-09-12 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022500425A JP2022500425A (ja) 2022-01-04
JP2022500425A5 true JP2022500425A5 (cg-RX-API-DMAC7.html) 2022-08-09
JP7361766B2 JP7361766B2 (ja) 2023-10-16

Family

ID=68240777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514019A Active JP7361766B2 (ja) 2018-09-14 2019-09-12 ヒト免疫不全ウイルス複製の阻害剤

Country Status (4)

Country Link
US (1) US20220089598A1 (cg-RX-API-DMAC7.html)
EP (1) EP3849982A1 (cg-RX-API-DMAC7.html)
JP (1) JP7361766B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020053811A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53973A (fr) 2018-10-24 2022-02-09 Viiv Healthcare Uk No 5 Ltd Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2020084491A1 (en) * 2018-10-24 2020-04-30 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
ES2969030T3 (es) * 2018-10-29 2024-05-16 Viiv Healthcare Uk No 5 Ltd Derivados de quinazolinil-indazol y su uso como inhibidores de replicación de virus de inmunodeficiencia humana
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2021070054A1 (en) * 2019-10-08 2021-04-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US12564595B2 (en) 2019-11-28 2026-03-03 Shionogi & Co., Ltd. Prophylactic and therapeutic pharmaceutical agent for HIV infectious diseases characterized by comprising combination of integrase inhibitor and anti-HIV agent
US20240327428A1 (en) * 2023-02-23 2024-10-03 Ascletis Bioscience Co., Ltd. Inhibitors of human immunodeficiency virus replication, method of making and method of using thereof
TW202448483A (zh) 2023-05-31 2024-12-16 美商基利科學股份有限公司 用於hiv之治療性化合物
AR132951A1 (es) 2023-06-15 2025-08-13 Viiv Healthcare Uk No 5 Ltd Métodos e intermedios para preparar compuestos
WO2025169059A1 (en) 2024-02-05 2025-08-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2943493B1 (en) 2013-01-09 2017-08-02 Gilead Sciences, Inc. Therapeutic compounds for the treatment of viral infections
TW201443037A (zh) * 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US9873680B2 (en) 2014-08-29 2018-01-23 Gilead Sciences, Inc. Therapeutic compounds
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019198024A1 (en) * 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
CA3108633A1 (en) * 2018-08-09 2020-02-13 Viiv Healthcare Uk (No 5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2022501370A5 (cg-RX-API-DMAC7.html)
JP2022505597A5 (cg-RX-API-DMAC7.html)
JP2022505841A5 (cg-RX-API-DMAC7.html)
JP2024543976A5 (cg-RX-API-DMAC7.html)
JP2013209405A5 (cg-RX-API-DMAC7.html)
JP2024514703A5 (cg-RX-API-DMAC7.html)
JP2022505989A5 (cg-RX-API-DMAC7.html)
JP2020534263A5 (cg-RX-API-DMAC7.html)
JP2024173998A5 (cg-RX-API-DMAC7.html)
JP2016527217A5 (cg-RX-API-DMAC7.html)
JP2018524339A5 (cg-RX-API-DMAC7.html)
JP2022545359A5 (cg-RX-API-DMAC7.html)
JP2025071130A5 (cg-RX-API-DMAC7.html)
JP2019509276A5 (cg-RX-API-DMAC7.html)
JP2021514373A5 (cg-RX-API-DMAC7.html)
JP2023543059A5 (cg-RX-API-DMAC7.html)
JP2016518437A5 (cg-RX-API-DMAC7.html)
JP2022505637A5 (cg-RX-API-DMAC7.html)
ES2670769T3 (es) Derivados de (hetero)arilacetamida como agentes antirretrovirales
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2016518434A5 (cg-RX-API-DMAC7.html)
JP2019518046A5 (cg-RX-API-DMAC7.html)
JP2017537949A5 (cg-RX-API-DMAC7.html)
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2013515074A5 (cg-RX-API-DMAC7.html)